Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
As part of our efforts to demonstrate the applicability of AJICAP®, we have been advancing joint research with RIBOMIC (disclosed on December 27, 2023) aimed at realizing next-generation aptamer pharmaceuticals. In this research, RIBOMIC has..